DOUGLAS LAMB: Open Payments
NPI 1912097288 · BEAUFORT, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$590 in 21 payments from 10 companies in 2025. Trend: 2023 $895 · 2024 $983 · 2025 $590
Food & beverage: $590
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $106 |
| GlaxoSmithKline, LLC. | 4 | $99 |
| Organogenesis Inc. | 2 | $66 |
| ABBVIE INC. | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $14 |
Products named: BREZTRI, CAPLYTA, TRELEGY ELLIPTA, VRAYLAR, AIRSUPRA, APLIGRAF, JARDIANCE, REXULTI.
Industry payments across NC — which companies pay providers there.
